BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 24658815)

  • 1. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.
    van de Donk NW; Palumbo A; Johnsen HE; Engelhardt M; Gay F; Gregersen H; Hajek R; Kleber M; Ludwig H; Morgan G; Musto P; Plesner T; Sezer O; Terpos E; Waage A; Zweegman S; Einsele H; Sonneveld P; Lokhorst HM;
    Haematologica; 2014 Jun; 99(6):984-96. PubMed ID: 24658815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
    Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
    Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
    Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
    Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
    Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal gammopathies of undetermined significance.
    Kyle RA; Rajkumar SV
    Best Pract Res Clin Haematol; 2005; 18(4):689-707. PubMed ID: 16026745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis and progression of monoclonal gammopathy of undetermined significance.
    Bladé J; Rosiñol L; Cibeira MT; de Larrea CF
    Leukemia; 2008 Sep; 22(9):1651-7. PubMed ID: 18668131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study.
    Kristinsson SY; Björkholm M; Andersson TM; Eloranta S; Dickman PW; Goldin LR; Blimark C; Mellqvist UH; Wahlin A; Turesson I; Landgren O
    Haematologica; 2009 Dec; 94(12):1714-20. PubMed ID: 19608666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.
    Cowan A; Ferrari F; Freeman SS; Redd R; El-Khoury H; Perry J; Patel V; Kaur P; Barr H; Lee DJ; Lightbody E; Downey K; Argyelan D; Theodorakakou F; Fotiou D; Liacos CI; Kanellias N; Chavda SJ; Ainley L; Sandecká V; Pospíšilová L; Minarik J; Jungova A; Radocha J; Spicka I; Nadeem O; Yong K; Hájek R; Kastritis E; Marinac CR; Dimopoulos MA; Get G; Trippa L; Ghobrial IM
    Lancet Haematol; 2023 Mar; 10(3):e203-e212. PubMed ID: 36858677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance : A Cohort Study Nested in a Clinical Trial.
    Eythorsson E; Rognvaldsson S; Thorsteinsdottir S; Einarsson Long T; Reed ER; Sigurdardottir GA; Vidarsson B; Onundarson PT; Agnarsson BA; Sigurdardottir M; Olafsson I; Thorsteinsdottir I; Sveinsdottir SV; Sigurdsson F; Thordardottir AR; Palsson R; Indridason OS; Jonsson A; Gislason GK; Olafsson A; Sigurdsson J; Steingrimsdottir H; Hultcrantz M; Durie BGM; Harding S; Landgren O; Aspelund T; Love TJ; Kristinsson SY
    Ann Intern Med; 2024 Apr; 177(4):449-457. PubMed ID: 38560901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review.
    Kaur J; Valisekka SS; Hameed M; Bandi PS; Varma S; Onwughalu CJ; Ibrahim H; Mongia H
    Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):e195-e212. PubMed ID: 36966041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for and diagnosis of monoclonal gammopathy.
    Chong YP; Lim SM; Loh TP; Mollee P; Wijeratne N; Choy KW
    J Clin Pathol; 2023 Nov; 76(11):727-733. PubMed ID: 37604683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal gammopathies of undetermined significance.
    Kyle RA; Rajkumar SV
    Rev Clin Exp Hematol; 2002 Sep; 6(3):225-52. PubMed ID: 12616697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Kyle RA; Rajkumar SV
    Oncology (Williston Park); 2011 Jun; 25(7):578-86. PubMed ID: 21888255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal Gammopathy of Undetermined Significance.
    Gonsalves WI; Rajkumar SV
    Ann Intern Med; 2022 Dec; 175(12):ITC177-ITC192. PubMed ID: 36508741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA
    Eur J Haematol Suppl; 1989; 51():70-5. PubMed ID: 2516809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: new criteria for differential diagnosis and risk stratification.
    Paiva B; Montes MC; García-Sanz R; Ocio EM; Alonso J; de Las Heras N; Escalante F; Cuello R; de Coca AG; Galende J; Hernández J; Sierra M; Martin A; Pardal E; Bárez A; Alonso J; Suarez L; González-López TJ; Perez JJ; Orfao A; Vidríales MB; San Miguel JF
    Leukemia; 2014 Jan; 28(1):166-73. PubMed ID: 23604227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple myeloma and multiple plasmacytomas associated with free gamma heavy chain, free kappa light chain and IgGk paraproteins: an unusual triple gammopathy.
    Deighan WI; O'Kane MJ; McNicholl FP; Keren DF
    Ann Clin Biochem; 2016 Nov; 53(6):706-711. PubMed ID: 27166317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.
    Kyle RA; Rajkumar SV
    Br J Haematol; 2007 Dec; 139(5):730-43. PubMed ID: 18021088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.